Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Introgen's tumour suppressor agent shows promising results

Introgen Therapeutics : 04 June, 2007  (New Product)
Promising Phase 1/2 clinical data for tumour suppressor agent INGN 241has been announced by Introgen Therapeutics.
INGN 241is Introgen's novel investigational mda-7/IL-24 tumour suppressor agent for patients with advanced solid tumors.

The data was presented at the annual meeting of the American Society of Gene Therapy and showed that in this 22-patient trial, INGN 241 induced killing in all treated tumours, including in those patients who failed prior therapy with other anti-cancer agents.

INGN 241 was well tolerated, and a maximum tolerated dose was not reached.

Tumour growth control was observed in 44 percent of treated tumours.
Two of five patients treated at the highest dose showed objective responses (greater than 50 percent reduction in tumour size).

Increases in the number of immune cells known to mediate anti-tumour effects were also observed in all patients, consistent with the immune-stimulating activity of INGN 241.

Although INGN 241 was administered directly to tumours, evidence of distant biologic activity was observed, suggesting that this therapy may have utility in treating primary tumours as well as metastatic disease.

INGN 241 treatment in combination with Radiotherapy is being evaluated in an ongoing Phase 3 trial in solid tumours, including patients with head and neck cancer.

'These data are particularly encouraging because they demonstrate INGN 241 has clinical activity even in patients who have failed previous therapies', said Sunil Chada, PhD, associate vice president, Clinical Research and Development at Introgen.

Data from preclinical studies of INGN 241 was also presented that evaluated the ability of INGN 241 to restore cisplatin sensitivity to ovarian cancer cells that are cisplatin-resistant.

The results showed that INGN 241 effectively kills cisplatin-resistant cells when used as monotherapy, and restores cisplatin sensitivity.
Cisplatin is one of the most commonly utilized treatments for lung, breast and colon cancers.

However, development of cisplatin resistance is a common event and the ability of INGN 241 to kill these resistant tumours and restore cisplatin efficacy has important clinical implications.

Previous INGN 241 preclinical studies have indicated similar synergies with other chemotherapies and with radiation treatment.

Dr Chada added, 'These preclinical data demonstrate that INGN 241 can restore sensitivity to cisplatin, a widely used chemotherapy drug that frequently gives rise to resistance'.

'Our findings support applications of INGN 241 in combination with standard chemotherapy and radiation regimens and we are planning future clinical trials based on these results'.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo